Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble
Grappling with the slow uptake of its constipation drug Trulance, Synergy Pharmaceuticals $SGYP has practically thrown in the towel saying that it does not anticipate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.